ReviewJournal of clinical and translational hepatology2022
Biomarkers of Metabolic (Dysfunction)-associated Fatty Liver Disease: An Update.
Review in Journal of clinical and translational hepatology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 24 citations in OpenAlex.
- Impact of metabolic dysfunction-associated steatotic liver disease on long-term prognosis in hepatocellular carcinoma patients undergoing hepatectomy.Hepatobiliary surgery and nutrition · 2026Article
- TASL practice guidance for the diagnosis and management of metabolic dysfunction-associated steatotic liver disease (MASLD).Hepatology forum · 2026Article
- Non-invasive blood biomarkers for assessment of liver fibrosis in metabolic dysfunction-associated steatotic liver disease.World journal of hepatology · 2025Review
- Unraveling Metabolic Dysfunction-Associated Steatotic Liver Disease Through the Use of Omics Technologies.International journal of molecular sciences · 2025Review
- Psoas Muscle Index, Systemic Inflammation, and Liver Fibrosis in MAFLD: A Case-Control Study.Diabetes, metabolic syndrome and obesity : targets and therapy · 2025Article
- MAFLD identifies patients with significant hepatic fibrosis better than MASLD.Hepatology international · 2024Article
- Article
- NAFLD in the 21st Century: Current Knowledge Regarding Its Pathogenesis, Diagnosis and Therapeutics.Biomedicines · 2024Review
- Proteome profiling to advance management of metabolic dysfunction-associated fatty liver disease.Hepatobiliary surgery and nutrition · 2024Article
- Meeting at the Crossroad between Obesity and Hepatic Carcinogenesis: Unique Pathophysiological Pathways Raise Expectations for Innovative Therapeutic Approaches.International journal of molecular sciences · 2023Review
- Prevalence and dynamics of NAFLD-associated fibrosis in people living with HIV in Vienna from first presentation to last follow-up.Wiener klinische Wochenschrift · 2023Article
- Sex dimorphism and metabolic profiles in management of metabolic-associated fatty liver disease.World journal of clinical cases · 2023Review
- Screening for MAFLD: who, when and how?Therapeutic advances in endocrinology and metabolism · 2023Review
- A Study of Biomarkers Associated with Metabolic Dysfunction-Associated Fatty Liver Disease in Patients with Type 2 Diabetes.Diagnostics (Basel, Switzerland) · 2022Article
- Epidemiology, natural history, and diagnosis of metabolic dysfunction-associated fatty liver disease: a comparative review with nonalcoholic fatty liver disease.Therapeutic advances in endocrinology and metabolism · 2022Review
- Serum high-sensitive C-reactive protein is a simple indicator for all-cause among individuals with MAFLD.Frontiers in physiology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The prevalence of metabolic (dysfunction)-associated fatty liver disease (MAFLD) is rapidly increasing and affects up to two billion individuals globally, and this has also resulted in increased risks for cirrhosis, hepatocellular carcinoma, and liver transplants. In addition, it has also been linked to extrahepatic consequences, such as cardiovascular disease, diabetes, and various types of cancers. However, only a small proportion of patients with MAFLD develop these complications. Therefore, the identification of high-risk patients is paramount. Liver fibrosis is the major determinant in developing these complications. Although, liver biopsy is still considered the gold standard for the assessment of patients with MAFLD. Because of its invasive nature, among many other limitations, the search for noninvasive biomarkers for MAFLD remains an area of intensive research. In this review, we provide an update on the current and future biomarkers of MAFLD, including a discussion of the associated genetics, epigenetics, microbiota, and metabolomics. We also touch on the next wave of multiomic-based biomarkers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.